Bioverativ buys rare blood disease firm | Chemical & Engineering News
Volume 95 Issue 22 | p. 15 | Concentrates
Issue Date: May 29, 2017

Bioverativ buys rare blood disease firm

Department: Business
Keywords: biologics, Bioverativ, biotech, pharmaceuticals

Seeking to become a leader in treating blood disorders, Bioverativ will pay $400 million up front to acquire privately held True North Therapeutics. Bioverativ, a Biogen spin-off, adds to its portfolio TNT009, a monoclonal antibody in early-stage studies for cold agglutinin disease, a rare form of anemia that occurs when autoantibodies attack red blood cells. True North investors could see another $425 million in milestone payments if TNT009 reaches the market.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment